All In Biotech

Drug Trial Radar · NCT06610526

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

731

Actual

Start

Aug 23, 2024

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to describe the efficacy and safety information with dapagliflozin in Chinese patients with chronic kidney disease.

Conditions

  • Chronic Kidney Disease

Interventions

  • DapagliflozinDrug

    Dapagliflozin by oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death.Time frame: Up to a median follow-up time of 24 months

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Dongguan, China

  • Research Site

    Foshan, China

  • Research Site

    Fuyang, China

  • Research Site

    Fuzhou, China

  • Research Site

    Ganzhou, China

  • Research Site

    Harbin, China

  • Research Site

    Hefei, China

  • Research Site

    Hengyang, China

  • Research Site

    Huaian, China

  • Research Site

    Huizhou, China

  • Research Site

    Jilin City, China

  • Research Site

    Jinan, China

  • Research Site

    Jining, China

  • Research Site

    Lanzhou, China

  • Research Site

    Linyi, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanning, China

  • Research Site

    Ningbo, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenzhen, China

  • Research Site

    Suzhou, China

  • Research Site

    Taian, China

  • Research Site

    Tianjin, China

  • Research Site

    Wuhu, China

  • Research Site

    Wuxi, China

  • Research Site

    Xi'an, China

  • Research Site

    Xiamen, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.